[lsaquo]Background[rsaquo]

ABO-incompatible living kidney transplantation (ABO-ILKT) has been performed to broaden the range of donor types used for living related kidney transplantation (LKT). Recently, ABO-ILKT has steadily become more widespread. However, the optimal immunosuppressive regimen for ABO-ILKT remains uncertain. We aimed to determine the longitudinal changes in the outcomes from ABO-ILKT compared with those from ABO-CLKTover the last 25 years.

[lsaquo]Patients and Methods[rsaquo]

Of 1465 patients who underwent living kidney transplantations (LKT) at three institutes between 1989 and 2013, 1277[mdash]including 306 ABO-ILKT and 971 ABO-CLKT cases[mdash]were evaluated for graft survival, patient survival, infectious adverse events, and renal function. The patients were divided into four groups according to the transplantation era and ABO-compatibility.

[lsaquo]Results[rsaquo]

In the past decade, ABO-ILKT and ABO-CLKT recipients yielded almost equivalent outcomes with respect to the 9-year graft survival rates, which were 89.3% and 89.1%, respectively, (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.49–1.94, p = 0.937). The graft survival rate for ABO-ILKT conducted between 2005 and 2013 was better than that for ABO-ILKT conducted between 1998 and 2004 (HR 0.32, 95% CI 0.15-0.68, p = 0.003). ABO-ILKT recipients showed substantial improvements in the graft survival rate over time. Graft survival was almost identical over the past decade, regardless of ABO-incompatibility.

[lsaquo]Conclusion[rsaquo]

Today, ABO-ILKT is an acceptable treatment for patients with end-stage renal disease.

CITATION INFORMATION: Tanabe K, Okumi M, Furusawa M, Unagami K, Hirai T, Shirakawa H, Shimizu T, Omoto K, Inui M, Ishida H. ABO-Incompatible Living Kidney Transplantation at Multicenter Japanese Case Series: Evolution of Outcomes and Immunosuppressive Management. Am J Transplant. 2016;16 (suppl 3).

« Back to 2016 American Transplant Congress